Separate terms with OR to return results that match either term.
 
Clear All

9,186 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Descending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68788-9770-03 68788-9770 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 27, 2012 Nov. 8, 2019 No Longer Used
68788-9770-05 68788-9770 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 27, 2012 Nov. 8, 2019 No Longer Used
69189-7732-01 69189-7732 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 4, 2016 May 24, 2017 No Longer Used
70518-0235-00 70518-0235 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 17, 2017 Nov. 9, 2018 In Use
70518-0291-00 70518-0291 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 8, 2017 March 14, 2019 In Use
70518-0291-01 70518-0291 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 16, 2017 May 17, 2018 In Use
70518-0654-00 70518-0654 Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous July 31, 2017 March 8, 2018 No Longer Used
70518-0892-00 70518-0892 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Oral Dec. 12, 2017 Jan. 6, 2020 No Longer Used
70518-1422-00 70518-1422 Ondansetron Hydrochloride Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Sept. 18, 2018 Oct. 11, 2019 In Use
70518-2895-00 70518-2895 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Sept. 25, 2020 In Use
70934-0206-83 70934-0206 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 6, 2020 In Use
70934-0206-87 70934-0206 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 19, 2019 In Use
70934-0206-88 70934-0206 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 15, 2019 In Use
70934-0206-95 70934-0206 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 4, 2019 In Use
70934-0206-99 70934-0206 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 12, 2019 In Use
70934-0294-84 70934-0294 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 29, 2020 In Use
70934-0294-95 70934-0294 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 22, 2019 In Use
70934-0448-83 70934-0448 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 8, 2020 In Use
70934-0448-95 70934-0448 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 26, 2020 In Use
70934-0634-82 70934-0634 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 18, 2020 In Use
70934-0634-95 70934-0634 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 31, 2020 In Use
75921-0459-10 75921-0459 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 In Use
23155-0547-31 23155-0547 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug. 22, 2016 In Use
23155-0547-41 23155-0547 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous June 15, 2012 In Use
23155-0547-42 23155-0547 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous June 15, 2012 In Use
23155-0548-31 23155-0548 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug. 22, 2016 In Use
23155-0548-41 23155-0548 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 9, 2015 In Use
23155-0548-42 23155-0548 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 9, 2015 In Use
70518-1551-00 70518-1551 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 23, 2018 In Use
70518-1551-01 70518-1551 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 1, 2019 In Use
72694-0954-01 72694-0954 Pegaspargase Oncaspar 750.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous Jan. 2, 2020 In Use
54482-0301-01 54482-0301 Pegaspargase Oncaspar 750.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous Feb. 1, 1994 Nov. 30, 2016 No Longer Used
00944-3810-01 00944-3810 Pegaspargase Oncaspar 750.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous Feb. 1, 1994 May 16, 2020 No Longer Used
00597-0143-60 00597-0143 Nintedanib Ofev 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGFR, PDGFR, FLT3, CSF1R Oral Oct. 17, 2014 In Use
00597-0145-60 00597-0145 Nintedanib Ofev 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Oral Oct. 17, 2014 In Use
00078-0645-15 00078-0645 Sonidegib Odomzo 200.0 mg/1 Chemotherapy Hedgehog Pathway Inhibitor SMO Oral July 24, 2015 Dec. 31, 2017 No Longer Used
23155-0685-31 23155-0685 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous Aug. 20, 2019 In Use
23155-0686-31 23155-0686 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous Aug. 20, 2019 In Use
62756-0093-40 62756-0093 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 7, 2012 Jan. 31, 2017 No Longer Used
62756-0093-44 62756-0093 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 31, 2012 Jan. 31, 2017 No Longer Used
62756-0094-40 62756-0094 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 7, 2012 Nov. 30, 2016 No Longer Used
62756-0094-44 62756-0094 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 31, 2012 Nov. 30, 2016 No Longer Used
62756-0095-40 62756-0095 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 7, 2012 Nov. 30, 2016 No Longer Used
62756-0095-44 62756-0095 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 31, 2012 Nov. 30, 2016 No Longer Used
00641-6177-01 00641-6177 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 8, 2005 In Use
00641-6178-01 00641-6178 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 8, 2005 In Use
00703-3333-01 00703-3333 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Nov. 23, 2005 In Use
00703-3343-01 00703-3343 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Nov. 23, 2005 In Use
00781-3166-71 00781-3166 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb. 4, 2014 In Use
00781-3166-95 00781-3166 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb. 4, 2014 In Use

Found 9,186 results in 20 millisecondsExport these results